Post on 04-Apr-2018
7/29/2019 Anticipating the competition in pharma
1/6
Anticipating the competition in pharma
Published on 14/03/11 at 07:30am
Jon Bircher
Dont be intimidated by the competition, and dont take them on head-to-head when it might not
be necessary
Sun Tzu, the ancient Chinese military strategist wrote: Conquerors estimate before thewar begins, and they consider everything; the defeated also estimate before the war, but
they do not consider everything. Estimating completely creates victory; estimating
incompletely causes failure. When we look at it from this point of view, it is very obvious
who will win the war.
This was often quoted in the context of business - with good reason, because in our increasingly
competitive marketplace, being successful requires the same kind of strategic discipline.
What is particularly apt about this quote is the estimating completely bit. In pharma marketingterms, this is about understanding as much as you can about what your competitors could do in
the future in order to make your strategy as robust as possible. Most marketers realise theimportance of gaining insight into their competitors, but translating todays insight into futureforesight, is much more revealing; helping us interpret what competitors could do.
The shift within pharma to more specialised markets highlights the need for companies to bring
brands to market swiftly, with a keen eye on the landscape, including possible competitors. At
the same time, the EMA has been quoted as wanting to encourage greater competition within the
7/29/2019 Anticipating the competition in pharma
2/6
sector to improve innovation, quality, value and diversity of treatments available for patients -
whilst applying scrutiny to strategies that are deemed as anti-competitive
So pre-empting the competition needs to be done in an appropriate anti-trust context (see sectionat end of article).
It is clear that in most situations we face competitors; but whereas in the past more specialist
areas have been less competitive than the big primary care markets, we are now seeing the same
level of competition in those areas too
This also translates into biotechnology with more companies becoming proficient, pluscompanies such as Pfizer highlighting their desire to be market leaders in this field. We are
increasingly working with companies facing a significant competitive threat in orphan and rare
disease markets, in which there was once just a few small companies competing.
So competition is stronger than ever, and in many ways that is very healthy. From a customer
perspective it helps keep medicines budgets under control, it provides greater innovation in thesystem, and on the whole it provides patients with access to better medicines. Using competitive
foresight to adapt your strategies will cause the competition to make their move, to which youwill need to adapt - and so it never stands still.
Know your competitor
In an ideal world, you would spend enough time looking at all your competitors in detail.
You would consider everybody in the market or who is planning to enter and try to gain an
understanding of them all. However, this is often not viable. So who are our core competitors?
Keep it simple; first, the market leader. Understand what they do to maintain that position, andsee how they drive, challenge and alter the market itself.
Secondly, consider the fastest growing competitor, what are they doing to grow and how are they
changing the market dynamic? What are they doing differently that is driving success?
Thirdly, if there new competitors entering the market, what is their likely strategy and how are
they shaping the market?
Finally, look at companies which are strategically significant, or have strategically significant
products. They may not be obvious competitors but they will have similar goals to you, making
them a disproportionately bigger threat. Although we often recognise that there is a need forcompetitive analysis, many companies have no formal way of collecting the data.
They rely on past experiences, or assumptions that are made internally, coupled with a gut
feeling. However, if we want to win the fight we need to gather data in a systematic way, withthe goal of using it to decode competitors future strategies. This is a big task, so the data needs
to be utilised effectively, otherwise it simply becomes an information-gathering exercise - which
is a little pointless.
7/29/2019 Anticipating the competition in pharma
3/6
The trick is to turn data into insight, and translate this into foresight. Insights are those deep,
penetrating things that you didnt previously understand that help you consider how to do
business differently, whereas foresight is understanding the implications of those nuggets for thefuture.
Understand your competitor
To understand your competitor, there are probably four buckets of insight you need to grab
which interrelate with each other to provide you with the foresight you need to consider theirstrategies moving forward.
The four areas to understand are:
The ambition of the company
Their organisational views of the world
Their current strategy
What they are good at.
Your competitors ambition will be central in influencing how they go about developing theirstrategy, and how they will react to competitors (i.e. your) moves.
One of the first questions you may want to consider are their financial goals; short term and long
term. This will tell you whether they are going for absolute market growth or whether they are
actually trying to gain as much profit from this product as they can.
What are their beliefs and values? What current pressures are they under? These will help you
understand their hot buttons if you threaten them - and equally, the areas where you could go
unnoticed or comfortably co-exist.
Whatis their attitude to risk? Understanding that, and how they react to competition, is a prettygood indicator of how they might react to your own strategies.
Decoding a companys goals and ambitions for the future is critical, because it ultimately helps
you formulate the most appropriate strategy yourself. Can you peacefully co-exist, and do you
want to? If not it helps you understand the consequences; if your competitor has a product which
is important to them strategically and emotionally, tackling them head-on will require acompletely different approach and skillset.
The second thing you need to understand is their organisational view of the world - how they
understand the marketplace, and even how they view themselves. If they have a particular viewof the way the market works, then you may be able to work out a strategy where you dont need
to take them on head-on, so they wont see you coming.
7/29/2019 Anticipating the competition in pharma
4/6
If, for example, their view of the world is that the whole patient voice piece is simply
irrelevant, and therefore they spend all their time and energy on the doctor, you may be able to
create a strategy which is about leveraging the patients voice, whilst going relatively unnoticed.You get to see the opportunities by looking at their blind-spots in their view of the world.
Identifying this view of the world is relatively straightforward. Look at how it communicatesabout itself, about its future, about the opportunities that exist. Where is it investing its energy
and its resources? How historically has the competition leveraged their offering? Howemotionally attached does it appear to be to this marketplace or this patient population?
Next comes their current strategy; understanding this will help you understand the strategy for
the future. Generally pharma marketers are pretty good at understanding the core components ofour direct competitors strategy; we are less good at considering it in the context of the overall
company.
There are lots of indicators of a company or product strategy. For example, chief executives like
to stand up and tell people about how clever their strategy is, what they are doing, and how theyare approaching it.
Is your competitor aiming for growth through focused knowledge and energy in a certain therapy
area or technology? Are they diversifying their portfolio and managing risk that way? If their
strategy is about becoming the number one bio-pharmaceutical company, what implications doesthat have on their future strategy? Are they going to be the key specialist in rare diseases, or in
personalised medicine?
When considering the most appropriate strategy for your business unit or brand you must also
consider the tier below, and the implications at business unit level. If they are a company that has
a broad strategy of diversification, but one particular business unit has real focus within a therapyarea, consider what pressures this exerts on the business unit, and how this influences their future
strategy.
The final part in the jigsaw is to understand what your competitors are good at. You can considera lot of different things at a whole company level, from the products they promote, their
marketing capabilities, their distribution network, their clinical trial programme, their corporate
management, or their financial positioning; down to the tactical level around their sales teamsand marketing materials.
This helps you understand how capable the company is at achieving its overall ambition - and the
possible areas of danger. If you go up against a company that has a fantastic, proactive legaldepartment which will take on anybody who tries to challenge their patent or their position in themarketplace, you have to recognise the degree of risk involved.
This is a quick look at the different areas to find competitive insight. You now need to look at
those four buckets together, play them out decoding the competitors future strategy so as to
optimise your own.
7/29/2019 Anticipating the competition in pharma
5/6
Generating fresh foresight
One of the best (and most interactive) ways of decoding strategy is through some kind of
simulation - we use competitor rooms. These can be run in many different ways depending onyour challenge, but essentially they involve playing out different scenarios and different
competitors.
They should use all the insight that you have gathered, internal knowledge and perspectives in
order to get under the competitors skin and generate genuine foresight. In a given situation, howwill this competitor react to our move? If we generate an aggressive market growth strategy what
are the reactions, the implications? What are the likely moves from competitor A and competitor
B when we implement a new segment-based approach?
Interaction is important. These sessions act as a test bed for what could happen in reality,whether simulating competitor reactions to your strategic moves or simulating changes from a
competitor, all will help you understand the strategic options available and their implications.
This then helps you decide the best strategy to put in place; for example, it may be because of
new competitive foresight, that you find a way to go unnoticed. Your price-based strategy canwork alongside their innovation and clinical-based strategy. Its not the space they own, its not
the space they compete in, and you go unnoticed. Equally, it is important to understand how they
will defend when you make a threatening move. What level of provocation will your attackcause, and therefore what is their likely retaliation?
If a company is really comfortable with its current approach, and it appears to be working for
them, they are going to be pretty reluctant to change it. However, if you hit them in a place
where they are sensitive, or vulnerable, you might move them out of that comfort zone and take
them on head-to-head when you didnt need to.
The idea of this whole exercise is not about just getting loads of granularity around the
competition for the sake of it; its actually about making sure your own strategy is as good as it
possibly can be, robust enough and with the right components - built on your learnings from acompetitive perspective.
Only when you have this level of understanding can you estimate completely and ensure the
strategy you build is as future proof as it possibly can be.
THE ETHICS OF COMPETITOR INTELLIGENCE
There is an increasing emphasis on regulation around competition, so shouldnt the pharmaindustry be nervous about trying to gain foresight in to their competitors likely behaviour?
It is true that there is a nervousness about anti-trust laws, especially when it comes to primary
competitive intelligence - employing people or organisations to speak to specific individuals.
7/29/2019 Anticipating the competition in pharma
6/6
It is important to point out that competitive analysis and competitive intelligence should not be
about breaking the law. Competitive intelligence is an ethical and legal business practice, as
opposed to industrial espionage which is illegal. It is also not about formulating strategies thatconflict with the anti-competitive laws. It is certainly not about predatory pricing or illegal trade
restrictions or M&A deals. Rather, its about understanding and anticipating your competitors in
such a way that you optimise your own strategy and approach.
Competition is healthy - because it keeps the market alive and keeps innovation happening - weneed to understand more about our competitors to optimise our own approach. And in optimising
our approach, they will inevitably optimise theirs.
The one thing you can rely on is that in a market with more than one product, the approach andstrategy of one company will be influenced by the other player or players in the market, and each
will react to the competitions moves.
So the whole interplay between the competition is in part what brings about better access to
medicines, better pricing and better innovation.
In other words, having an insight into what your competitors are doing doesnt lead to the stiflingof competition, rather it provides future foresight that actually enhances the competition and
potentially ups everyones game.